" />
Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01 - CISMeF
Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01NCIt concept
Preferred Label : Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01;
NCIt related terms : CHO-H01;
NCIt definition : A glyco-engineered monoclonal antibody directed against the human B-cell-specific
cell surface antigen CD20, with potential antineoplastic and immunomodulating activities.
Upon administration of glyco-engineered anti-CD20 monoclonal antibody CHO H01, the
antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated
cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis
and the inhibition of tumor cell proliferation. In addition, CHO H01 inhibits CD20-mediated
signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing
tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively
expressed on B-cells during most stages of B-cell development, is often overexpressed
in B-cell malignancies. The Fc-glycans are homogenously engineered onto the antibody
and increase ADCC, anti-tumor activity and the half-life of the antibody.;
Semantic type(s)